Physician profile
Oscar B Lahoud
NPI 1972731776
$64,818.99
in general payments reported to CMS, 2019-2025
17 companies · $50K in 2025
The $50K reported for 2025 was more than what 93% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2021: $1,453 · 2023: $13K · 2024: $357 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,056 · Travel and Lodging: $3,992 · Food and Beverage: $3,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,961.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,056.00 |
| Travel and Lodging | $3,991.78 |
| Food and Beverage | $3,118.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $27,157.50 | 2025 | Yescarta |
| Incyte Corporation | $14,304.09 | 2023-2025 | Monjuvi |
| Janssen Biotech, INC. | $8,577.45 | 2019-2025 | Carvykti, Rybrevant, Talvey |
| Genzyme Corporation | $5,137.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $4,142.88 | 2023-2025 | Blenrep, Arexvy, Ojjaara |
| Pfizer INC. | $2,551.00 | 2025 | |
| Morphosys, US INC. | $1,437.50 | 2021 | |
| Sobi, INC | $563.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $279.27 | 2024-2025 | Calquence |
| Genentech USA, INC. | $145.79 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $138.18 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $129.99 | 2025 | |
| Boston Scientific Corporation | $114.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.71 | 2025 | |
| Adc Therapeutics America, INC. | $52.63 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $15.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Lahoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.